| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-13-0044 |
| P8608 | Fatcat ID | release_fazelsf4pjhdthot5i64zdpesq |
| P932 | PMC publication ID | 3823187 |
| P698 | PubMed publication ID | 23966292 |
| P5875 | ResearchGate publication ID | 256076386 |
| P50 | author | Lecia V Sequist | Q90926732 |
| Patricia Greninger | Q91735291 | ||
| P2093 | author name string | Jeffrey Settleman | |
| Meng Wang | |||
| Lee Zou | |||
| Liliana Gheorghiu | |||
| Cyril H Benes | |||
| Henning Willers | |||
| Kerstin Borgmann | |||
| Heike N Pfäffle | |||
| Natalie Ferraiolo | |||
| P2860 | cites work | Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2 | Q24337575 |
| A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair | Q24337655 | ||
| EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment | Q24338426 | ||
| Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair | Q25257863 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway | Q28203777 | ||
| Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights | Q28252640 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments | Q33520771 | ||
| Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy | Q33598694 | ||
| DNA interstrand crosslink repair in mammalian cells: step by step | Q33669915 | ||
| Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair | Q33762568 | ||
| FAN1 Acts with FANCI-FANCD2 to Promote DNA Interstrand Cross-Link Repair | Q34128701 | ||
| New driver mutations in non-small-cell lung cancer | Q34161395 | ||
| Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway | Q34285356 | ||
| Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors | Q34309488 | ||
| BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. | Q34449830 | ||
| Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies | Q34550979 | ||
| An oncogene-induced DNA damage model for cancer development | Q34759268 | ||
| Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway | Q34835796 | ||
| Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated | Q35741383 | ||
| Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial | Q36097426 | ||
| DNA interstrand crosslink repair and cancer | Q36576047 | ||
| Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells | Q36982835 | ||
| First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. | Q37729803 | ||
| FANCP/SLX4: a Swiss army knife of DNA interstrand crosslink repair | Q37870047 | ||
| Biomarkers and mechanisms of FANCD2 function | Q38287129 | ||
| EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks | Q38609721 | ||
| In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status | Q39526236 | ||
| FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons | Q39574588 | ||
| The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links | Q39807128 | ||
| AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. | Q39916383 | ||
| Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma | Q40124686 | ||
| Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase | Q40401323 | ||
| Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and biochemical characteristics | Q40484333 | ||
| Mechanism of RAD51-dependent DNA interstrand cross-link repair. | Q41070024 | ||
| Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype | Q42481495 | ||
| Detection of impaired homologous recombination repair in NSCLC cells and tissues. | Q43246772 | ||
| Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer | Q46225965 | ||
| Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae | Q46540743 | ||
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 | ||
| Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition | Q64388338 | ||
| The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin | Q64388522 | ||
| Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors | Q80315104 | ||
| EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations | Q81562470 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| P304 | page(s) | 6254-6263 | |
| P577 | publication date | 2013-08-21 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity | |
| P478 | volume | 73 |
| Q92877857 | Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity |
| Q36073749 | DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity |
| Q39846614 | Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation |
| Q42513590 | EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair |
| Q92241385 | EGFR exon 19-deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non-small cell lung cancer |
| Q26768267 | Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors |
| Q41964099 | Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells |
| Q92027154 | Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization |
| Q64087613 | Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer |
| Q40456709 | Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis. |
| Q28540769 | Preclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomography |
| Q64988279 | Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. |
| Q103826099 | Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer |
| Q34453444 | Structural insights into 5' flap DNA unwinding and incision by the human FAN1 dimer |
| Q89861185 | Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation |
Search more.